Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.67 |
| ▸ | EDNRB | P24530 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716850 | 0.82 | EDNRA (1.00) | EDNRAEDNRBMEN1KMT2ACYP2C9 | |
| SCHEMBL1789659 | 0.81 | TTR (0.76) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL1791652 | 0.80 | TTR (0.81) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL1792241 | 0.80 | MAPT (0.76) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL2184492 | 0.79 | MAPT (0.75) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL1791237 | 0.79 | TTR (0.76) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL15095989 | 0.78 | TTR (0.71) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL1791643 | 0.78 | MAPT (0.76) | MAPTPOLBGFERMEN1KMT2A | |
| SCHEMBL6152009 | 0.77 | EDNRA (1.00) | EDNRAEDNRBMEN1KMT2ACYP2C9 | |
| SCHEMBL3135247 | 0.76 | MAPT (0.70) | MAPTPOLBGFERMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | EDNRA 588/4885EDNRB 486/4885MAPT 443/4885 |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | EDNRA 588/4885EDNRB 486/4885MAPT 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.